Targeted protein degraders of SARS-CoV-2 Mpro are more active than enzymatic inhibition alone with activity against nirmatrelvir resistant virus

Author(s):

Baolong Pan, Simon J. Mountford, Maki Kiso, Danielle E. Anderson, Georgina Papadakis, Kate E. Jarman, Danielle R. Tilmanis, Belinda Maher, Thomas Tran, Jake Shortt, Seiya Yamayoshi, Yoshihiro Kawaoka, Philip E. Thompson, Sam A. Greenall, Nadia Warner

Details:

Communications Medicine, Volume 5, Issue 1, 2025-12-01, Article number 140

Article Link: Click here

Affiliations:

• The University of Tokyo
• Massachusetts Institute of Technology
• University of Melbourne
• Monash University
• Walter and Eliza Hall Institute of Medical Research
• National Center for Global Health and Medicine
• Monash Health
• University of Wisconsin School of Veterinary Medicine
• The Peter Doherty Institute for Infection and Immunity
• The Institute of Medical Science, The University of Tokyo